{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:31:15Z","timestamp":1785598275194,"version":"3.56.0"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,3,13]]},"abstract":"<jats:p> PURPOSE: To evaluate the safety and efficacy of weekly docetaxel in women with metastatic breast cancer. <\/jats:p><jats:p> PATIENTS AND METHODS: Twenty-nine women were enrolled onto a study of weekly docetaxel given at 40 mg\/m<jats:sup>2<\/jats:sup>\/wk. Each cycle consisted of 6 weeks of therapy followed by a 2-week treatment break, repeated until disease progression or removal from study for toxicity or patient preference. Fifty-two percent of patients had been previously treated with adjuvant chemotherapy; 21% had received prior chemotherapy for metastatic breast cancer, and 31% had previously received anthracyclines. All patients were assessable for toxicity; two patients were not assessable for response but are included in an intent-to-treat analysis. <\/jats:p><jats:p> RESULTS: Patients received a median of 18 infusions, with a median cumulative docetaxel dose of 720 mg\/m<jats:sup>2<\/jats:sup>. There were no complete responses. Twelve patients had partial responses (overall response rate, 41%; 95% confidence interval, 24% to 61%), all occurring within the first two cycles. Similar response rates were observed among subgroups of patients previously treated either with any prior chemotherapy or with anthracyclines. An additional 17% of patients had stable disease for at least 6 months. The regimen was generally well tolerated. There was no grade 4 toxicity. Only 28% of patients had any grade 3 toxicity, most commonly neutropenia and fatigue. Acute toxicity, including myelosuppression, was mild. Fatigue, fluid retention, and eye tearing\/conjunctivitis became more common with repetitive dosing, although these side effects rarely exceeded grade 2. Dose reductions were made for eight of 29 patients, most often because of fatigue (n = 5). <\/jats:p><jats:p> CONCLUSION: Weekly docetaxel is active in treating patients with metastatic breast cancer, with a side effect profile that differs from every-3-weeks therapy. <\/jats:p>","DOI":"10.1200\/jco.2000.18.6.1212","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:16:39Z","timestamp":1487920599000},"page":"1212-1219","source":"Crossref","is-referenced-by-count":200,"title":["Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer"],"prefix":"10.1200","volume":"18","author":[{"given":"Harold J.","family":"Burstein","sequence":"first","affiliation":[{"name":"From the Breast Oncology Center; Departments of Adult Oncology and Biostatistical ScienceDana-Farber Cancer Institute; Department of Medicine, Brigham & Women\u2019s Hospital; Division of Hematology\/Oncology, Massachusetts General Hospital; and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Manola","sequence":"additional","affiliation":[{"name":"From the Breast Oncology Center; Departments of Adult Oncology and Biostatistical ScienceDana-Farber Cancer Institute; Department of Medicine, Brigham & Women\u2019s Hospital; Division of Hematology\/Oncology, Massachusetts General Hospital; and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Younger","sequence":"additional","affiliation":[{"name":"From the Breast Oncology Center; Departments of Adult Oncology and Biostatistical ScienceDana-Farber Cancer Institute; Department of Medicine, Brigham & Women\u2019s Hospital; Division of Hematology\/Oncology, Massachusetts General Hospital; and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leroy M.","family":"Parker","sequence":"additional","affiliation":[{"name":"From the Breast Oncology Center; Departments of Adult Oncology and Biostatistical ScienceDana-Farber Cancer Institute; Department of Medicine, Brigham & Women\u2019s Hospital; Division of Hematology\/Oncology, Massachusetts General Hospital; and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Bunnell","sequence":"additional","affiliation":[{"name":"From the Breast Oncology Center; Departments of Adult Oncology and Biostatistical ScienceDana-Farber Cancer Institute; Department of Medicine, Brigham & Women\u2019s Hospital; Division of Hematology\/Oncology, Massachusetts General Hospital; and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Scheib","sequence":"additional","affiliation":[{"name":"From the Breast Oncology Center; Departments of Adult Oncology and Biostatistical ScienceDana-Farber Cancer Institute; Department of Medicine, Brigham & Women\u2019s Hospital; Division of Hematology\/Oncology, Massachusetts General Hospital; and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[{"name":"From the Breast Oncology Center; Departments of Adult Oncology and Biostatistical ScienceDana-Farber Cancer Institute; Department of Medicine, Brigham & Women\u2019s Hospital; Division of Hematology\/Oncology, Massachusetts General Hospital; and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy E.","family":"Garber","sequence":"additional","affiliation":[{"name":"From the Breast Oncology Center; Departments of Adult Oncology and Biostatistical ScienceDana-Farber Cancer Institute; Department of Medicine, Brigham & Women\u2019s Hospital; Division of Hematology\/Oncology, Massachusetts General Hospital; and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn D.","family":"Clarke","sequence":"additional","affiliation":[{"name":"From the Breast Oncology Center; Departments of Adult Oncology and Biostatistical ScienceDana-Farber Cancer Institute; Department of Medicine, Brigham & Women\u2019s Hospital; Division of Hematology\/Oncology, Massachusetts General Hospital; and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence N.","family":"Shulman","sequence":"additional","affiliation":[{"name":"From the Breast Oncology Center; Departments of Adult Oncology and Biostatistical ScienceDana-Farber Cancer Institute; Department of Medicine, Brigham & Women\u2019s Hospital; Division of Hematology\/Oncology, Massachusetts General Hospital; and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[{"name":"From the Breast Oncology Center; Departments of Adult Oncology and Biostatistical ScienceDana-Farber Cancer Institute; Department of Medicine, Brigham & Women\u2019s Hospital; Division of Hematology\/Oncology, Massachusetts General Hospital; and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.2.314"},{"key":"R2-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.58"},{"key":"R3-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.422"},{"key":"R4-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2879"},{"key":"R5-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2886"},{"key":"R6-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.10.2643"},{"key":"R7-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.9.3149"},{"key":"R8-0172","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.416"},{"key":"R9-0172","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008370930599"},{"key":"R10-0172","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10113-7"},{"key":"R11-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1127"},{"key":"R12-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1858"},{"key":"R13-0172","unstructured":"Winer  E,  Berry  D,  Duggan  D, et al:  Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer:  Results from CALGB 9342. Proc Am Soc Clin Oncol 17:101a,1998  (abstr 388)"},{"key":"R14-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3353"},{"key":"R15-0172","doi-asserted-by":"crossref","unstructured":"Klaasen  U,  Wilke  H,  Strumberg  D, et al:  Phase I study with a weekly 1-h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer.  Eur J Cancer 32A:547,1996-549,","DOI":"10.1016\/0959-8049(95)00641-9"},{"key":"R16-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.187"},{"key":"R17-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.7.1458"},{"key":"R18-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2164"},{"key":"R19-0172","unstructured":"L\u00f6ffler  TM,  Freund  W,  Droge  C, et al:  Activity of weekly Taxotere (TXT) in patients with metastatic breast cancer.  Proc Am Soc Clin Oncol 17:113a,1998  (abstr 435)"},{"key":"R20-0172","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008260515869"},{"key":"R21-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.12.1935"},{"key":"R22-0172","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010544"},{"key":"R23-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2341"},{"key":"R24-0172","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1413"},{"key":"R25-0172","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00122-7"},{"key":"R26-0172","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.37"},{"key":"R27-0172","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058907"},{"key":"R28-0172","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10113-7"},{"key":"R29-0172","unstructured":"Climent  CA,  Ruiz  A,  Llombart-Cusac  A, et al:  Weekly docetaxel in patients with advanced malignancies:  Toxicity profile and activity results. Proc Am Soc Clin Oncol 18:119a,1999  (abstr 453)"},{"key":"R30-0172","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199506000-00001"},{"key":"R31-0172","doi-asserted-by":"crossref","unstructured":"Perez  EA:  Paclitaxel in breast cancer.  The Oncologist 3:373,1998-389,","DOI":"10.1634\/theoncologist.3-6-373"},{"key":"R32-0172","unstructured":"Perez  EA,  Irwin  DH,  Patel  R, et al:  A large phase II trial of paclitaxel administered as a weekly one hour infusion to patients with metastatic breast cancer.  Proc Am Soc Clin Oncol 18:126a,1999  (abstr 480)"},{"key":"R33-0172","unstructured":"Norton  L:  Kinetic concepts in the systemic drug therapy of breast cancer.  Semin Oncol 26:11,1999-20,   (suppl 2)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.6.1212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:41:54Z","timestamp":1653514914000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.6.1212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3,13]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,3,13]]}},"alternative-id":["10.1200\/JCO.2000.18.6.1212"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.6.1212","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3,13]]}}}